Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Profiling of Oncogenic Signaling in Multiple Myeloma — Association with Biology, Disease Progression and Prognosis

Nicola Lehners, Jing Xu, Thomas Hielscher, Leo Rasche, Elena Ellert, Albrecht Stenzinger, Peter Schirmacher, Carsten Müller-Tidow, MD, Hartmut Goldschmidt, MD, Mindaugas Andrulis, Niels Weinhold, PhD, Marc S Raab, MD

Blood (2018) 132 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2018-99-116214

Published: 2018

Journal Articles

Prospective Investigation of Genetic Alterations in Osteolytic Lesions Compared to Paired Random Aspirates

Sandra Sauer, MD, Jens Hillengass, MD, Barbara Wagner, Daniel Spira, MD, Marc Andre Weber, MD, Stefan Hemmer, Stefan Delorme, MD, Jennifer Mosebach, MD, Martin Freitag, MD, Antonia Strauss-Dimitrakopoulou, Hartmut Goldschmidt, MD, Mindaugas Andrulis, MD, Brian Durie, MD, Dirk Hose, MD, Anja Seckinger, MD

Blood (2016) 128 (22): 4419.

https://doi.org/10.1182/blood.V128.22.4419.4419

Published: 2016

Journal Articles

Oncogene Induced Senescence As a Potential Breakpoint Mechanism Against Malignant Transformation in Plasma Cell Disorders

Nicola Lehners, MD, Elena Ellert, MD, Jing Xu, Hartmut Goldschmidt, MD, Mindaugas Andrulis, MD, Marc S. Raab, MD

Blood (2016) 128 (22): 4474.

https://doi.org/10.1182/blood.V128.22.4474.4474

Published: 2016

Journal Articles

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

K. Martin Kortüm, Elias K. Mai, Nur H. Hanafiah, Chang-Xi Shi, Yuan-Xiao Zhu, Laura Bruins, Santiago Barrio, Patrick Jedlowski, Maximilian Merz, Jing Xu, Robert A. Stewart, Mindaugas Andrulis, Anna Jauch, Jens Hillengass, Hartmut Goldschmidt, P. Leif Bergsagel, Esteban Braggio, A. Keith Stewart, Marc S. Raab

Blood (2016) 128 (9): 1226–1233.

https://doi.org/10.1182/blood-2016-02-698092

Published: 2016

Includes: Supplemental data

Journal Articles

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Blood (2016) 127 (23): 2847–2855.

https://doi.org/10.1182/blood-2015-11-680074

Published: 2016

Includes: Supplemental data

Journal Articles

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

Marc S. Raab, Nicola Lehners, Jing Xu, Anthony D. Ho, Peter Schirmacher, Hartmut Goldschmidt, Mindaugas Andrulis

Blood (2016) 127 (17): 2155–2157.

https://doi.org/10.1182/blood-2015-12-686782

Published: 2016

Includes: Supplemental data

Journal Articles

Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways

Blood (2015) 126 (23): 723.

https://doi.org/10.1182/blood.V126.23.723.723

Published: 2015

Journal Articles

Recurrent CDKN1B (p27) mutations in hairy cell leukemia

Blood (2015) 126 (8): 1005–1008.

https://doi.org/10.1182/blood-2015-04-643361

Published: 2015

Includes: Supplemental data

Journal Articles

Signaling Pathway Profiling in Multiple Myeloma

Marc S Raab, MD, Jing Xu, MSc, Thomas Hielscher, Nicola Lehners, MD, Elena Ellert, MD, Anthony D. Ho, MD FRCPC, Peter Schirmacher, MDPhD, Hartmut Goldschmidt, MD, Mindaugas Andrulis, MD

Blood (2014) 124 (21): 644.

https://doi.org/10.1182/blood.V124.21.644.644

Published: 2014

Journal Articles

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Dietrich Sascha, MD, Andreas Pircher, MD, Mindaugas Andrulis, MD, Elena Ellert, MD, Frédéric Peyrade, Clemens-Martin Wendtner, MD, George A Follows, Martin JS Dyer, Thomas Elter, MD, Robert Zeiser, Anita Gaehler, MD, Michael Herrmann, Michael Herold, MDPhD, Claire Dearden, MD, Hanno Glimm, MD, Michael Hallek, MD, Anthony D Ho, MD, Michael Steurer, Thorsten Zenz, MD

Blood (2014) 124 (21): 3634.

https://doi.org/10.1182/blood.V124.21.3634.3634

Published: 2014

Journal Articles

Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia

Sascha Dietrich, MD, Jennifer Hüllein, Michael Hundemer, Nicola Lehners, MD, Alexander Jethwa, David Capper, MD, Till Acker, MD, Boyan Garvalov, PhD, Mindaugas Andrulis, MD, Carolin Blume, Julia Meissner, MD, Stefan Fröhling, MD, Christof von Kalle, MD, Hanno Glimm, MD, Anthony D. Ho, MD, Thorsten Zenz, MD

Blood (2012) 120 (21): 4600.

https://doi.org/10.1182/blood.V120.21.4600.4600

Published: 2012

Journal Articles

The Proliferation Inhibitor CDKN1C (P57KIP2) Is Over Expressed in CD34+ Cells of Patients with MDS and Determines a Worse Prognosis Independently of IPSS Score Factors

Sascha Dietrich, MD, Mindaugas Andrulis, MD, Andrea Pellagatti, PhD, Aleksandar Radujkovic, MD, Ulrich Germing, MD, Stephan Baldus, MD, Thomas Giese, MD, Jacqueline Boultwood, MD, Peter H Krammer, PhD, Peter Dreger, MD, Anthony D. Ho, MD, Thomas Luft, MD

Blood (2012) 120 (21): 3820.

https://doi.org/10.1182/blood.V120.21.3820.3820

Published: 2012

Journal Articles

BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications

Nicola Lehners, MD, Mindaugas Andrulis, MD, David Capper, MD, Andreas von Deimling, MD, Anthony D Ho, MD, Hartmut Goldschmidt, MD, Kai Neben, MD, Marc S Raab, MD

Blood (2012) 120 (21): 4040.

https://doi.org/10.1182/blood.V120.21.4040.4040

Published: 2012

Journal Articles

Endothelial Stress in Steroid-Refractory Gvhd: A Burden Statins Cannot Lift

Sascha Dietrich, MD, Axel Benner, Dipl.Stat, Christine Falk, Michael Hess, Mindaugas Andrulis, Berend H. Isermann, MD, Anthony D. Ho, MD, PhD, Peter Dreger, MD, Thomas Luft

Blood (2011) 118 (21): 1012.

https://doi.org/10.1182/blood.V118.21.1012.1012

Published: 2011

Journal Articles

Correlation of Bone Marrow Cellularity, Plasma Cell Infiltration and Microcirculation with Apparent Diffusion Coefficient of Diffusion Weighted Imaging In Patients with Monoclonal Plasma Cell Disease

Jens Hillengass, Bram Stieltjes, Tobias Baeuerle, Fabienne McClanahan, Christiane Heiss, Mindaugas Andrulis, Reiner Bartl, Rajiv Shah, Dirk Simon, Dirk Hose, Anthony D. Ho, MD, FRCPC, Heinz Peter Schlemmer, Hartmut Goldschmidt, Stefan Delorme

Blood (2010) 116 (21): 2978.

https://doi.org/10.1182/blood.V116.21.2978.2978

Published: 2010

Journal Articles

Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.

Tanja Heimberger, Mindaugas Andrulis, Stephanie Fischbach, Thorsten Stühmer, Hermann Einsele, Ralf C. Bargou, Manik Chatterjee

Blood (2009) 114 (22): 2829.

https://doi.org/10.1182/blood.V114.22.2829.2829

Published: 2009

Journal Articles

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

Angela Zöllinger, Thorsten Stühmer, Manik Chatterjee, Stefan Gattenlöhner, Eugenia Haralambieva, Hans-Konrad Müller-Hermelink, Mindaugas Andrulis, Axel Greiner, Carmen Wesemeier, Jörg C. Rath, Hermann Einsele, Ralf C. Bargou

Blood (2008) 112 (8): 3403–3411.

https://doi.org/10.1182/blood-2007-11-119362

Published: 2008

Includes: Supplemental data

Journal Articles

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

Manik Chatterjee, Christoph Rancso, Thorsten Stühmer, Niels Eckstein, Mindaugas Andrulis, Christian Gerecke, Heike Lorentz, Hans-Dieter Royer, Ralf C. Bargou

Blood (2008) 111 (7): 3714–3722.

https://doi.org/10.1182/blood-2007-05-089151

Published: 2008

Includes: Supplemental data

Journal Articles

Role and Regulation of Heat Shock Proteins 90alpha and 90beta in Multiple Myeloma.

Manik Chatterjee, MD, Sarika Jain, Thorsten Stühmer, PhD, Mindaugas Andrulis, MD, Ute Ungethüm, MD, Ralf-Jurgen Kuban, PhD, Kurt Bommert, PhD, Max Topp, MD, Doris Krämer, MD, Hans K. Müller-Hermelink, MD, Herrmann Einsele, MD, Greiner Axel, MD, Ralf C. Bargou, MD

Blood (2006) 108 (11): 5029.

https://doi.org/10.1182/blood.V108.11.5029.5029

Published: 2006

Journal Articles

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival

Manik Chatterjee, Sarika Jain, Thorsten Stühmer, Mindaugas Andrulis, Ute Ungethüm, Ralf-Jürgen Kuban, Heike Lorentz, Kurt Bommert, Max Topp, Doris Krämer, Hans Konrad Müller-Hermelink, Hermann Einsele, Axel Greiner, Ralf C. Bargou

Blood (2006) 109 (2): 720–728.

https://doi.org/10.1182/blood-2006-05-024372

Published: 2006

NARROW

Profiling of Oncogenic Signaling in Multiple Myeloma — Association with Biology, Disease Progression and Prognosis

Prospective Investigation of Genetic Alterations in Osteolytic Lesions Compared to Paired Random Aspirates

Oncogene Induced Senescence As a Potential Breakpoint Mechanism Against Malignant Transformation in Plasma Cell Disorders

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways

Recurrent CDKN1B (p27) mutations in hairy cell leukemia

Signaling Pathway Profiling in Multiple Myeloma

BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib

Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia

The Proliferation Inhibitor CDKN1C (P57KIP2) Is Over Expressed in CD34+ Cells of Patients with MDS and Determines a Worse Prognosis Independently of IPSS Score Factors

BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications

Endothelial Stress in Steroid-Refractory Gvhd: A Burden Statins Cannot Lift

Correlation of Bone Marrow Cellularity, Plasma Cell Infiltration and Microcirculation with Apparent Diffusion Coefficient of Diffusion Weighted Imaging In Patients with Monoclonal Plasma Cell Disease

Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

Role and Regulation of Heat Shock Proteins 90alpha and 90beta in Multiple Myeloma.

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only